Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 5/20 | 0.58 |
| ▸ | IGF1R | P08069 | 2/20 | 0.58 |
| ▸ | AURKA | O14965 | 4/20 | 0.57 |
| ▸ | CDK7 | P50613 | 4/20 | 0.57 |
| ▸ | CDK9 | P50750 | 4/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.57 |
| ▸ | CDK4 | P11802 | 3/20 | 0.57 |
| ▸ | CDK1 | P06493 | 3/20 | 0.56 |
| ▸ | FLT3 | P36888 | 8/20 | 0.56 |
| ▸ | JAK2 | O60674 | 4/20 | 0.56 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.56 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.56 |
| ▸ | LCK | P06239 | 2/20 | 0.56 |
| ▸ | WEE1 | P30291 | 2/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.56 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | PAK4 | O96013 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659614 | 0.89 | JAK2 (0.61) | CDK2CDK4JAK2PRKD3LCK | |
| Hydrochloric Acid SCHEMBL660445 | 0.88 | JAK2 (0.60) | CDK2CDK4JAK2PRKD3LCK | |
| SCHEMBL14755163 | 0.87 | EGFR (0.54) | CDK2JAK2PRKD3LCKJAK3 | |
| SCHEMBL10245417 | 0.85 | PRKD3 (0.56) | CDK2IGF1RAURKACDK7CDK9 | |
| SCHEMBL10192761 | 0.84 | JAK2 (0.59) | CDK2CDK4JAK2PRKD3LCK | |
| SCHEMBL10245770 | 0.81 | JAK2 (0.62) | CDK2CDK4JAK2KDRGSK3B | |
| SCHEMBL13253313 | 0.80 | JAK2 (0.67) | CDK2AURKACDK7CDK9AURKB | |
| SCHEMBL4380243 | 0.80 | JAK2 (0.83) | CDK2IGF1RAURKACDK7CDK9 | |
| SCHEMBL10246683 | 0.80 | JAK2 (0.61) | CDK2CDK4JAK2KDRGSK3B | |
| SCHEMBL10346528 | 0.80 | CDK2 (0.57) | CDK2IGF1RAURKACDK7CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130059824-A1 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120270844-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270844-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | PSEN2, MAPT, PSEN1 | CDK2 2797/4885IGF1R 4055/4885AURKA 2855/4885 |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | CDK2 2683/4885IGF1R 4731/4885AURKA 4702/4885 |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | PAK2, PAK3, PAK4 | CDK2 2811/4885IGF1R 4794/4885AURKA 2716/4885 |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | CDK2 502/4885IGF1R 4561/4885AURKA 1235/4885 |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | PAK2, PAK3, PAK4 | CDK2 2477/4885IGF1R 4774/4885AURKA 4649/4885 |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | SMN1; SMN2, PYGB, PMP22 | CDK2 2984/4885IGF1R 4814/4885AURKA 3121/4885 |
| US-20130059824-A1 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | CHAT, PSEN2, PAK2 | CDK2 1099/4885IGF1R 4095/4885AURKA 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.